RESUMO
The action of ghrelin on telemetrically recorded motor activity and the transmission of the effects of this neuropeptide on spontaneous and exploratory motor activity and some related endocrine and homeostatic parameters were investigated. Different doses (0.5-5 microg) of ghrelin administered intracerebroventricularly caused significant increases in both square crossing and rearing activity in the "open-field" apparatus, while only the dose of 5 microg evoked a significant increase in the spontaneous locomotor activity recorded by telemetry. Ghrelin also induced significant increases in corticosterone release and core temperature. To determine the transmission of these neuroendocrine actions, the rats were pretreated with different antagonists, such as a corticotropin-releasing hormone (CRH) antagonist (alpha-helical CRH(9-41)), the nitric oxide synthase inhibitor Nomega-nitro-L-arginine-methyl ester (L-NAME), haloperidol, cyproheptadine or the cyclooxygenase inhibitor noraminophenazone (NAP). The open-field and biotelemetric observations revealed that the motor responses were diminished by pretreatment with the CRH antagonist and haloperidol. In the case of HPA (hypothalamic pituitary adrenal) activation, only cyproheptadine pretreatment proved effective; haloperidol and L-NAME did not modify the corticosterone response. NAP had only a transient, while cyproheptadine elicited a more permanent impact on the hyperthermic response evoked by ghrelin; the other antagonists proved to be ineffective. The present data suggest that both CRH release and dopaminergic transmission may be involved in the ghrelin-evoked behavioral responses. On the other hand, ghrelin appears to have an impact on the HPA response via a serotonergic pathway and on the hyperthermic response via a cyclooxygenase and a serotonergic pathway.
Assuntos
Comportamento Animal/efeitos dos fármacos , Regulação da Temperatura Corporal/efeitos dos fármacos , Sistema Endócrino/efeitos dos fármacos , Hormônios Peptídicos/farmacologia , Aminopirina/farmacologia , Animais , Corticosterona/sangue , Hormônio Liberador da Corticotropina/sangue , Inibidores de Ciclo-Oxigenase/farmacologia , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Grelina , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Hormônios Estimuladores de Melanócitos/sangue , Atividade Motora/efeitos dos fármacos , Neuropeptídeo Y/sangue , Óxido Nítrico/metabolismo , Hormônios Peptídicos/administração & dosagem , Ratos , Ratos Wistar , Serotonina/metabolismoRESUMO
As the distribution of apelinergic neurons in the brain suggests an important role of apelin-13 in the regulation of neuroendocrine processes, in the present experiments the effects of this recently identified neuropeptide on the open-field activity, the hypothalamo-pituitary-adrenal (HPA) system and the body temperature were investigated. I.c.v. administration of apelin-13 (1-10 microg) to rats caused significant increases in square crossing, rearing, plasma corticosterone release and core temperature, whereas it did not influence the spontaneous motor activity during telemetric observation. To determine the mediation of the actions of apelin, a corticotropin-releasing hormone (CRH) antagonist, the nonselective dopamine antagonist haloperidol, the selective dopamine D1 receptor antagonist SCH-23390 and the nitric oxide synthase inhibitor Nomega-nitro-L-arginine-methyl ester (L-NAME) were administered to the rats. The apelin-evoked HPA activation was diminished by preadministration of the CRH antagonist, while the dopamine antagonist and L-NAME attenuated only the square crossing and rearing induced by apelin-13. To characterize the transmission of the thermoregulatory action of apelin, animals were pretreated either with L-NAME, the CRH antagonist or with the cyclooxygenase inhibitor noraminophenazone. L-NAME and the CRH antagonist did not cause significant inhibition of the apelin-evoked increase in core temperature, while the cyclooxygenase inhibitor, applied 30 min before peptide treatment, did not prove effective in preventing the apelin-evoked thermoregulatory response, whereas when it was administered 2 h after the peptide treatment, it transiently and significantly reduced the hyperthermic response. The present data suggest that apelin-13 plays an important role in the regulation of behavioral, endocrine and homeostatic responses in the CNS, and dopamine, nitric oxide and prostaglandins seem to take part in the mediation of its effects. Since the corticosterone response could be blocked by the CRH antagonist, it is likely to be mediated through the activation of the CRH neurons.
Assuntos
Comportamento Animal/efeitos dos fármacos , Regulação da Temperatura Corporal/efeitos dos fármacos , Proteínas de Transporte/farmacologia , Sistemas Neurossecretores/efeitos dos fármacos , Animais , Corticosterona/antagonistas & inibidores , Corticosterona/sangue , Hormônio Liberador da Corticotropina/farmacologia , Antagonistas de Dopamina/farmacologia , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Interações Medicamentosas , Inibidores Enzimáticos/farmacologia , Comportamento Exploratório/efeitos dos fármacos , Haloperidol/farmacologia , Injeções Intraperitoneais/métodos , Peptídeos e Proteínas de Sinalização Intercelular , Masculino , Atividade Motora/efeitos dos fármacos , NG-Nitroarginina Metil Éster/farmacologia , Fragmentos de Peptídeos/farmacologia , Ratos , Ratos WistarRESUMO
Previous publications have demonstrated a prominent central and corticotropin releasing hormone-mediated action of the endomorphins (EMs) on both open-field behaviour and the hypothalamo-pituitary-adrenal (HPA) axis. In the present experiments, the direct action of endomorphin-1 (EM1) on pituitary adrenocorticotropic hormone (ACTH) release, adrenal corticosterone secretion and the roles of nitric oxide (NO) and dopamine (DA) in the HPA and behavioural responses elicited by EM1 were investigated in mice. In vitro perifusion studies indicated that the action of EM1 on the HPA system appears to be confined to the hypothalamus, as EM1 did not influence the corticosterone secretion from adrenal slices and moderately attenuated the ACTH release from anterior pituitary slices. In in vivo experiments, NG-nitro-L-arginine (L-NNArg) pretreatment brought about a profound inhibition of both the endocrine and the behavioural responses. On the other hand, haloperidol completely abolished the increases in square crossing and rearing, without affecting corticosterone release. The direct action of EM1 on striatal DA release was therefore also investigated in an in vitro superfusion system. Although EM1 did not influence the basal release of tritiated DA, it significantly enhanced the transmitter release evoked by electric impulses and pretreatment with L-NNArg resulted in a considerable inhibition of the release elicited by EM1. In conclusion, our endocrine studies suggest an important role of NO in the mediation of the EM1-evoked corticosterone secretion. They also indicate that EM1 activates the HPA axis at a hypothalamic level and dopamine is not involved in this process. In contrast, the behavioural experiments reflect that the locomotor activation induced by EM1 is mediated by NO and dopamine, and the superfusion studies demonstrate that NO transmits the dopamine release enhancing effect of EM1.
Assuntos
Dopamina/fisiologia , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Óxido Nítrico/fisiologia , Oligopeptídeos/farmacologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Hormônio Adrenocorticotrópico/sangue , Animais , Dopamina/metabolismo , Inibidores Enzimáticos/farmacologia , Sistema Hipotálamo-Hipofisário/fisiologia , Masculino , Camundongos , Atividade Motora/fisiologia , Óxido Nítrico/antagonistas & inibidores , Sistema Hipófise-Suprarrenal/fisiologiaRESUMO
The effects and the mediation of the action of the proenkephalin derivative Met(5)-enkephalin-Arg(6)-Phe(7) (MERF) on the hypothalamo-pituitary-adrenal (HPA) system and open-field behavior were investigated in mice. Intracerebroventricular injection of the heptapeptide increased square crossing, rearing, and plasma corticosterone level. To characterize the receptors involved in these neuroendocrine processes, animals were pretreated either with the nonselective opioid antagonist naloxone or the kappa-antagonist nor-binaltorphimine (nor-BNI). Both antagonists dose-dependently attenuated the HPA activation elicited by MERF. Naloxone also blocked the behavioral responses, but nor-binaltorphimine did not elicit a significant inhibition. The dopamine antagonist haloperidol and a corticotropin-releasing hormone (CRH) antagonist were also preadministered to shed light on the transmission of the actions of MERF. Both the motor responses and the HPA activation were diminished by the preadministration of the CRH antagonist, while haloperidol attenuated only square crossing and rearing. To investigate the direct effect of MERF on the dopaminergic system, dopamine release of striatal slices was measured in a superfusion system. Neither the basal nor the electric impulse-evoked dopamine release was modified by MERF. The results suggest that opioid-mediation predominate in the neuroendocrine actions of MERF, and the effect of the heptapeptide on the HPA system seems to be mediated by kappa-receptors. In the behavioral responses evoked by MERF, both CRH release and the action of the dopaminergic neurons of the subcortical motor system might be involved. MERF also appears to activate the paraventricular CRH neurons, but dopaminergic transmission does not seem to play a significant role in its hypothalamic action.
Assuntos
Encefalina Metionina/análogos & derivados , Encefalina Metionina/farmacologia , Comportamento Exploratório/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Naltrexona/análogos & derivados , Antagonistas de Entorpecentes/farmacologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Análise de Variância , Animais , Comportamento Animal/efeitos dos fármacos , Hormônio Liberador da Corticotropina/farmacologia , Dopamina/metabolismo , Haloperidol/farmacologia , Antagonistas de Hormônios/farmacologia , Masculino , Camundongos , Atividade Motora/fisiologia , Naloxona/farmacologia , Naltrexona/farmacologia , Neostriado/efeitos dos fármacos , Neostriado/metabolismo , Técnicas de Cultura de Órgãos , Fragmentos de Peptídeos/farmacologiaRESUMO
The effects of intracerebroventricularly administered endomorphin-2 (EM2) on open-field activity and the hypothalamo-pituitary-adrenal (HPA) system were investigated. EM2 (0.25-1 microg) significantly increased both the locomotor and the rearing activity, resulting in a bell-shaped dose-response curve. EM2 also enhanced corticosterone release, with an even more profound downturn phase at higher concentrations. The corticotropin-releasing hormone (CRH) antagonist alpha-helical CRH9-41 completely abolished the EM2-evoked endocrine and behavioral responses. These findings reinforce the hypothesis that the endomorphins may play a significant role in the regulation of locomotion, rearing activity and the HPA system through the release of CRH.
Assuntos
Analgésicos Opioides/farmacologia , Hormônio Liberador da Corticotropina/farmacologia , Atividade Motora/efeitos dos fármacos , Oligopeptídeos/farmacologia , Fragmentos de Peptídeos/farmacologia , Animais , Corticosterona/sangue , Hormônio Liberador da Corticotropina/antagonistas & inibidores , Relação Dose-Resposta a Droga , Interações Medicamentosas , Injeções Intraventriculares , Masculino , Camundongos , Camundongos Endogâmicos , Oligopeptídeos/administração & dosagem , Oligopeptídeos/síntese química , Receptores Opioides mu/agonistas , Fatores de TempoRESUMO
The effects of endomorphin-1 (EM1) on behavioral responses and on the hypothalamic-pituitary-adrenal system were investigated in mice. Locomotor activity was measured in an "open-field" apparatus, with parallel recording of the numbers of rearings and groomings. Different doses of the peptide (250 ng to 5 microg) were administered to the animals intracerebroventricularly 30 min before the tests. EM1 caused significant increases in the locomotor activity and the number of rearings. The effect of EM1 on the basal corticosterone secretion was also investigated. At a dose of 5 microg, the peptide significantly increased plasma corticosterone level. The corticotropin-releasing hormone (CRH) antagonist alpha-helical CRH9-41, applied 30 min prior to EM1 administration, completely abolished the increases in both locomotion and the number of rearings and attenuated the corticosterone release evoked by EM1. These results suggest that the EM1 -induced increases in locomotion and rearing activity as well as the pituitary-adrenal activation are mediated by CRH.
Assuntos
Glândulas Suprarrenais/efeitos dos fármacos , Comportamento Animal/efeitos dos fármacos , Hipotálamo/efeitos dos fármacos , Oligopeptídeos/farmacologia , Hipófise/efeitos dos fármacos , Glândulas Suprarrenais/fisiopatologia , Animais , Corticosterona/sangue , Hormônio Liberador da Corticotropina/antagonistas & inibidores , Hormônio Liberador da Corticotropina/farmacologia , Hipotálamo/fisiologia , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Oligopeptídeos/administração & dosagem , Hipófise/fisiologia , Receptores Opioides mu/agonistasRESUMO
The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal (HPA) activation was investigated in the rat. The HPA system was stimulated by intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) and the plasma concentration of corticosterone was used as an index of the degree of activation. i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions of the antagonist and the antiserum were revealed by the dose-response curve; the highest concentrations practically abolished the HPA activation evoked by the orexins. These data suggest that the HPA system-stimulating effect of the orexins may be mediated by NPY.
Assuntos
Proteínas de Transporte/farmacologia , Sistema Hipotálamo-Hipofisário/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular , Neuropeptídeo Y/análogos & derivados , Neuropeptídeo Y/metabolismo , Neuropeptídeos/farmacologia , Sistema Hipófise-Suprarrenal/metabolismo , Animais , Anticorpos/farmacologia , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Neuropeptídeo Y/imunologia , Neuropeptídeo Y/farmacologia , Orexinas , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
The effects of the recently identified neuropeptides orexin-A and orexin-B on the hypothalamic-pituitary-adrenal (HPA) system were investigated. An in vivo system was used to assess the central effects of both orexin-A and orexin-B. Different doses of the orexins (2.8-560 pmol) were administered intracerebroventricularly (i.c.v.) to adult male rats, and plasma corticosterone was used as an index of the degree of the activation of the HPA system. Both peptides exhibited a clear dose-response action, although orexin-B proved to be less effective than orexin-A. Pretreatment with the corticotropin-releasing hormone (CRH) antagonist alpha-helical CRH9-41 completely prevented the action of the orexins. Orexin-A, orexin-B or adrenocorticotropic hormone (ACTH) was further administered intraperitoneally (i.p.). While ACTH evoked a significant adrenal response, the orexins did not influence the basal secretion. Adrenal slices, oxygenized and perifused with Krebs' solution, were also treated with orexin-A, orexin-B or ACTH. Both orexins failed to modify the release of corticosterone, but ACTH induced a marked adrenal response. This study suggests that these appetite-regulating peptides might activate the HPA system at a central level but neither orexin-A nor orexin-B appears to modulate directly the adrenal corticosterone release.
Assuntos
Proteínas de Transporte/farmacologia , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intracelular , Neuropeptídeos/farmacologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Animais , Corticosterona/metabolismo , Hormônio Liberador da Corticotropina/farmacologia , Antagonistas de Hormônios/farmacologia , Sistema Hipotálamo-Hipofisário/metabolismo , Sistema Hipotálamo-Hipofisário/fisiologia , Técnicas In Vitro , Injeções Intraperitoneais , Injeções Intraventriculares , Masculino , Orexinas , Fragmentos de Peptídeos/farmacologia , Sistema Hipófise-Suprarrenal/metabolismo , Sistema Hipófise-Suprarrenal/fisiologia , Ratos , Ratos WistarRESUMO
The aim of this study was to characterize the effects of brain natriuretic peptide (BNP) on the hypothalamo-pituitary-adrenal (HPA) responses to different stress paradigms (ether stress, electric shock and restraint). Rats were subjected to the stressful stimuli after intracerebroventricular administration of BNP (32.5 ng-6.5 microg) and plasma corticosterone was used as an indicator of the HPA activation. BNP did not modify the basal secretion, but inhibited the stress-induced rise in plasma corticosterone in a dose-dependent manner. BNP proved most effective in decreasing the corticosterone response to ether stress and attenuated the electric shock and restraint-induced HPA activation to a lesser extent. These results confirm the view that BNP takes part in the regulation of the HPA system.
Assuntos
Peptídeo Natriurético Encefálico/farmacologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Animais , Corticosterona/sangue , Relação Dose-Resposta a Droga , Eletrochoque , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Peptídeo Natriurético Encefálico/administração & dosagem , Ratos , Ratos Wistar , Restrição Física , Estresse Psicológico/fisiopatologiaRESUMO
The effects of C-type natriuretic peptide (CNP) on the hypothalamo-pituitary-adrenal system response to different stressors was studied. Various doses of CNP (0.2, 2, 4 microg) were injected into the lateral cerebral ventricle of freely moving rats 30 min before stress and activation of the adrenal was measured by plasma corticosterone. CNP did not affect basal corticosterone secretion in the doses applied, but inhibited in a dose-dependent manner the increase in plasma corticosterone induced by ether stress, electric shock and restraint. CNP exerted a more profound inhibitory effect on the response to ether stress than on that to electric shock or restraint. These results suggest that CNP acts centrally and to a different extent on the responses to different stresses.
Assuntos
Peptídeo Natriurético Tipo C/farmacologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Animais , Corticosterona/sangue , Relação Dose-Resposta a Droga , Eletrochoque , Éter/toxicidade , Injeções Intraventriculares , Masculino , Peptídeo Natriurético Tipo C/administração & dosagem , Sistema Hipófise-Suprarrenal/metabolismo , Ratos , Ratos Wistar , Restrição Física , Estresse Psicológico/sangue , Estresse Psicológico/metabolismoRESUMO
An analysis has been made of the nationalities of the members of advisory and editorial boards of analytical chemistry journals. Correlations were sought between their number and citation rates and between their number and the number of analytical papers published by scientists from the country in question. A comparison is given for the gatekeepers of organic and inorganic chemistry journals.